Metaplastic Tuft Cells in Pancreatic Cancer

Information

  • Research Project
  • 10124342
  • ApplicationId
    10124342
  • Core Project Number
    R01CA247516
  • Full Project Number
    7R01CA247516-02
  • Serial Number
    247516
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    3/9/2020 - 4 years ago
  • Project End Date
    2/28/2025 - a month from now
  • Program Officer Name
    SATHYAMOORTHY, NEERAJA
  • Budget Start Date
    3/19/2021 - 3 years ago
  • Budget End Date
    2/28/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    6/8/2021 - 3 years ago
Organizations

Metaplastic Tuft Cells in Pancreatic Cancer

Abstract Pancreatic ductal adenocarcinoma (PDA) is the 3rd most common cause of cancer-related death in the United States. This dismal outcome is in part due to the lack of understanding of the unique pathology of PDA that includes pronounced epithelial plasticity and evolution of an extensive reactive fibroinflammatory stroma. We have discovered an unusual cell type within preneoplasia and neoplasia known as the metaplastic tuft cell (MTC), which has been proposed to act as both a tumor initiating cell and as a chemosensory cell that drives the fibroinflammatory host response. Normal tuft cells are found in normal glandular tissues and are marked by the expression of the microtubule kinase DCLK1. There they sample the luminal environment and respond to signals by modifying the Type 2 immune response. While there are no tuft cells found in the normal pancreas, they arise in a transdifferentiation event to become part of the metaplastic and neoplastic epithelium during oncogenesis or tissue injury. Besides their chemosensory function, they have been hypothesized to be a tumor initiating progenitor cell. In order to definitively determine the origins and functions of the metaplastic tuft cell, we have created a dual recombinase driven mouse model of pancreatic neoplasia combined with an inducible Cre recombinase that specifically targets MTCs that will allow us to alternatively trace and target the metaplastic tuft cells independent of neoplastic transformation in vivo. We have also devised human and mouse organoid culture systems that preserve tuft cell differentiation, so that we can study their genesis, fate and chemosensory function in more detail. Together, these tools will be used to rigorously determine the function of the metaplastic tuft cell and whether manipulating their functions can be used to treat pancreatic cancer.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    7
  • Direct Cost Amount
    315566
  • Indirect Cost Amount
    152259
  • Total Cost
    467825
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:467825\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    HENRY FORD HEALTH SYSTEM
  • Organization Department
  • Organization DUNS
    073134603
  • Organization City
    DETROIT
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    482023450
  • Organization District
    UNITED STATES